We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.99%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
+$273M
Cap. Flow
+$275M
Cap. Flow %
11.97%
Top 10 Hldgs %
43.45%
Holding
85
New
20
Increased
27
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$73.7M
2
ABT icon
Abbott
ABT
+$49.7M
3
BLUE
bluebird bio
BLUE
+$40.7M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$37.3M
5
TFX icon
Teleflex
TFX
+$35.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.2M
2
AET
Aetna Inc
AET
+$37.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$34.4M
4
MOH icon
Molina Healthcare
MOH
+$31.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.29%
2 Financials 1.18%
3 Miscellaneous 0.94%
4 Communication Services 0.58%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$245M 10.64%
19,113,864
+1,557,278
+9% +$17.7M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$144M 6.27%
10,025,770
-986,791
-9% -$13.6M
PBYI icon
3
Puma Biotechnology
PBYI
$468M
$90.3M 3.93%
913,573
+6,931
+0.8% +$776K
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$89.8M 3.9%
1,320,027
+323,417
+32% +$22.6M
WVE icon
5
Wave Life Sciences
WVE
$993M
$77.5M 3.37%
2,209,107
-58,600
-3% -$1.71M
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$74.5M 3.24%
6,505,766
+29,000
+0.4% +$324K
AZN icon
7
AstraZeneca
AZN
$252B
$70.2M 3.05%
1,010,800
-112,350
-10% -$7.58M
INSM icon
8
Insmed
INSM
$25.9B
$70.1M 3.05%
2,249,262
+257,616
+13% +$7.61M
IMGN
9
DELISTED
Immunogen Inc
IMGN
$69.9M 3.04%
10,906,962
+2,845,465
+35% +$17.5M
CELG
10
DELISTED
Celgene Corp
CELG
$68.1M 2.96%
+653,000
New +$73.7M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$61.8M 2.69%
1,156,021
-687,712
-37% -$40.2M
PEN icon
12
Penumbra
PEN
$12.7B
$58.1M 2.53%
617,279
+51,768
+9% +$5.13M
CNC icon
13
Centene
CNC
$32B
$54.6M 2.37%
1,083,000
+273,800
+34% +$13.3M
ABT icon
14
Abbott
ABT
$195B
$51.2M 2.23%
+896,900
New +$49.7M
ATRA icon
15
Atara Biotherapeutics
ATRA
$92.3M
$51M 2.22%
112,640
-2,948
-3% -$1.09M
LIVN icon
16
LivaNova
LIVN
$4.43B
$49.2M 2.14%
615,588
-16,900
-3% -$1.34M
RGNX icon
17
Regenxbio
RGNX
$638M
$47.4M 2.06%
1,425,272
-242,400
-15% -$7.3M
SYNH
18
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$46.5M 2.02%
1,067,318
+799,400
+298% +$37.3M
BLUE
19
DELISTED
bluebird bio
BLUE
$46.3M 2.01%
+20,057
New +$40.7M
IRTC icon
20
iRhythm Holdings
IRTC
$3.96B
$45.7M 1.98%
814,574
+262,533
+48% +$13.7M
TFX icon
21
Teleflex
TFX
$5.92B
$42.9M 1.87%
172,486
+141,121
+450% +$35.5M
CTLT
22
DELISTED
CATALENT, INC.
CTLT
$34.2M 1.49%
833,063
+685,400
+464% +$27.9M
FATE icon
23
Fate Therapeutics
FATE
$291M
$33.4M 1.45%
5,465,486
+4,046,428
+285% +$18.1M
UNH icon
24
UnitedHealth
UNH
$353B
$32.8M 1.42%
148,620
+146,800
+8,066% +$31.1M
CBIO
25
Crescent Biopharma
CBIO
$659M
$32.4M 1.41%
19,307
+7,166
+59% +$9.48M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2017 Portfolio in Review

As of Q4 2017, Redmile Group held 85 positions worth $2.3B, up 13% from $2.03B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $275M of net new capital in Q4 2017, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was Celgene Corp: 653,000 shares worth $68.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $40.2M trimmed.

  • Redmile Group's largest Q4 2017 buy was Celgene Corp: 653,000 shares worth $68.1M.
  • Redmile Group added most to Syneos Health, Inc. Class A Common Stock in Q4 2017, an estimated $37.3M increase.
  • Redmile Group's biggest Q4 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $40.2M.
  • Redmile Group fully exited Aetna Inc in Q4 2017, selling an estimated $37.2M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q4 2017.
  • Redmile Group opened 20 new positions and closed 15 in Q4 2017.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.